Novartis: India's IP record steering R&D to China; Xenome struggles to regroup after trial failure;

@FierceBiotech: Will the biotech dealmaking lull extend through the rest of the year? More | Follow @FierceBiotech

@JohnCFierce: Novartis lashes out at India's patent rulings, says country is losing R&D. But India clearly doesn't care about R&D. More | Follow @JohnCFierce

@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. Article | Follow @RyanMFierce

@EmilyMFierce: Inovio vaccine kills malaria, boosts immune response in animals. Story | Follow @EmilyMFierce

> Novartis ($NVS) India Vice Chairman and Managing Director Ranjit Shahani laid out a threatening message to the country's lawmakers, noting that India's track record on drug IP was costing the subcontinent significant R&D investments by Big Pharma. "What we certainly would like to see is an ecosystem that fosters innovation and fast-track courts to hear and decide cases involving IPR. China has drawn all the leading global companies to invest in R&D there while India has not. That itself should serve as food for thought," he said. Story

> Australia's Xenome is trying to regroup after the clinical failure of its experimental drug for postsurgery pain. Company execs say they'll need a partner in order to refocus their work. Story

Medical Device News

@FierceMedDev: Special report: Device-tax worries aside, major med tech mostly added jobs in 2012. Feature | Follow @FierceMedDev

@DamianFierce: How can early-phase CROs brave a tough market? We asked two of the biggest. Editor's corner | Follow @DamianFierce

@MarkHFierce: Orthofix is in trouble again, this time for not filing its financials on time. Press release | Follow @MarkHFierce

@MichaelGFierce: Last week's Chutes & Ladders roundup: Pharma veteran Jeffrey Jonas takes top spot at Sage & more in biotech/pharma hirings. More | Follow @MichaelGFierce

> Abbott closes $250M deal for eye surgery biz. Article

> St. Jude snags Endosense for up to $331M. Report

> Cigna policy change risks hammering Myriad's Dx bottom line. Story

Pharma News

@FiercePharma: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Article | Follow @FiercePharma

@EricPFierce: India to consider putting handcuffs on foreign investment to protect domestic generics market. Story | Follow @EricPFierce

@CarlyHFierce: Merck stops selling Zilmax to study livestock drug's safety; the drug added $159M to sales in 2012. News | Follow @CarlyHFierce

> FTC asks to file brief in Effexor case, testing Supreme Court's pay-for-delay ruling. More

> Fresenius inks deal for 51% stake in Indonesian drugmaker. Item

CRO News

> Quintiles buying Novella with eye on emerging biotechs. More

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Article

> Risk-based monitoring could be a boon to CROs. Item

> Boehringer pulls plug on VA commercial plant. Story

> Express Scripts sells CRO biz to private equity outfit. More

> WuXi ratchets up expectations after banner quarter. News

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Report

Biotech IT News

> RTI wins NIH support to advance web-based toolkit for genetics research. News

> India's InterpretOmics scores $1.6M round to fuel bioinformatics biz. Report

> Pfizer taps online marketplace for outsourcing research. Story

> FDA's former IT boss nails down industry gig. More

> Certara, provider of drug research software, buys Michigan rival. Article

And Finally… Michigan State's Michael Feig has been studying how natural DNA repair can prevent cancer. Release